Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News

April 24, 2015
Women in Failed PrEP Trial Lied About Pill Use to Stay In Study
Female participants in a failed study of Truvada as pre-exposure prophylaxis (PrEP) often lied about their pill use in order to remain in the study.
April 23, 2015
ARVs Cut HIV Transmission Risk By 67% in Chinese Real-World Study
A Chinese study of the real-world effects of antiretroviral treatment's capacity to reduce the risk of HIV transmission has found it halves the risk, and in more recent years treatment led to a two-thirds risk reduction.
April 22, 2015
HIV Ages Immune Cell DNA by 14 Years
Untreated HIV causes changes to cellular DNA that are akin to 14 years of aging, which may partially explain the early onset of age-related diseases among people living with the virus.
European Liver Group Issues New Hep C Treatment Guidelines
The European Association for the Study of the Liver has issued revised guidelines for the treatment of hepatitis C.
April 21, 2015
HIV Researcher Questions Prevailing Wisdom About the Virus
A major HIV researcher has challenged colleagues to question various perceptions about the virus and its treatment in hopes of spurring new research channels.
April 20, 2015
Good Mental Health Likely Means Good Adherence to HIV Meds
Psychological wellbeing emerged as the only factor that predicted good adherence to HIV antiretrovirals in a recent study.
April 17, 2015
HIV Antibody Infusion Shows Promise in Treating The Virus
A single infusion of a broadly neutralizing HIV antibody has reduced viral loads for up to four weeks among HIV-positive individuals.
April 16, 2015
Intervention Improves HIV Med Adherence Among Blacks and Latinos
A counseling-based intervention has succeeded in improving adherence to antiretrovirals among HIV-positive blacks and Latinos who are reluctant to start treatment.
April 15, 2015
Poll of HIV Providers Finds Some Reluctance Toward PrEP Prescribing
A poll of HIV specialists has found evidence of less than full-fledged enthusiasm with regards to prescribing PrEP, depending on the patient group.
April 14, 2015
Statins May Cut Heart Disease Risk in HIV-Positive People
Research increasingly suggests that statins can prevent the advancement of coronary atherosclerosis among HIV-positive people.
April 13, 2015
Program Succeeds at Better Keeping People With HIV in Medical Care
A program designed to rate the rate of HIV-positive people who stay in routine medical care has succeeded, and at a cost deemed reasonable.
April 10, 2015
NIH Funds Research Into 'Kick and Kill' HIV Cure Strategy
The National Institutes of Health has pledged $6.6 million to support the first human clinical trial into a cure strategy known as “kick and kill.”
April 09, 2015
HIV Treatment Guidelines Nix Atripla as First-Line Therapy
A revision of U.S. HIV treatment guidelines has removed Atripla (efavirenz/tenofovir/emtricitabine) from the priority list of first-line antiretrovirals.
April 08, 2015
Gilead Applies for FDA Approval of New Version of Truvada
Gilead Sciences has filed for FDA approval of a new version of the dual-combination HIV antiretroviral Truvada that is less toxic to the bones and kidneys.
April 07, 2015
Early HIV Replication in the Brain Supports Hasty Treatment Start
HIV can replicate and evolve in the brain soon after infection, according to a recent analysis of cerebral spinal fluid, which helps illuminate such activity in the brain.
April 06, 2015
Kids Who Start HIV Treatment With Low CD4s Largely Regain Them
HIV-positive children who have low CD4 counts when starting treatment by and large experience a rebound to normal levels of those immune cells.
April 03, 2015
Effective Two-Drug HIV Regimen Sets Stage for Long-Acting Treatment
For those with fully suppressed HIV, switching to a two-drug regimen of cabotegravir and Edurant (rilpivirine) works as well taking a triple regimen based on Sustiva (efavirenz).
April 02, 2015
No Matter How You Slice It, PrEP Rollout Should Save Money
Canadian research suggests that rolling out Truvada as PrEP to prevent HIV would save money even if the cost to treat the virus drops in the future.
April 01, 2015
Risk Factors for Hep C Acquisition Among HIV-Positive Gay Men
Condomless receptive intercourse, ulcerative STIs, fisting and sharing sex toys are all linked with  acquiring hepatitis C among HIV-positive gay men.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Do you ever talk about HIV on social media?

Side Effects

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2015 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.